Member Info for wozzer70

🧩 PHASE 1 - Effectiveness (uncertainty removed)

Phase 1: Effectiveness

This is where uncertainty gets taken off the table.

Not a rerate yet - but the moment the process becomes real.

🧩 PHASE 2 - IPO Pricing (first benchmark)

Phase 2: IPO pricing

First real valuation for GDNT.

This is where TEK’s SOTP starts moving from assumptions to something measurable.

🧩 PHASE 3 - Price Discovery (market decides)

Phase 3: Price discovery

Once GDNT is trading, the market sets the value - not models, not opinions.

This is where the discount starts to get tested.

🧩 PHASE 4 - Rerate (if gap is clear)

Phase 4: Rerate

If the valuation gap is obvious, this is where TEK begins to adjust.

Not instant - but this is where momentum can build.

🧩 PHASE 5 - Monetisation (the endgame)

Phase 5: Monetisation

This is where value gets realised over time.

The rerate is the reaction - monetisation is the outcome.

TEK’s look‑through stakes in MicroSalt + Guident + GenIP + Lucyd are worth multiples of the current market cap on today’s prices and latest SEC filings. The main missing piece is a live Guident NASDAQ valuation to close that gap.

For me the story is simple: Guident moving from Tek’s internal/book value to a live NASDAQ price is the key catalyst. Once the market can see a screen price for GDNT, the discount to TEK’s SOTP has to be re‑examined.

The IPO is the Starting Point, Not the Finish Line.

As we enter the final "Power Window" for Guident’s ($GDNT) SEC Effectiveness, remember this: the IPO isn’t just about the listing - it’s about Rerating and Monetisation.

The Immediate Rerate: The IPO is the catalyst for the market to recognise the true value of Tekcapital’s stake, bridging the 60%+ discount to the 26p+ NAV.

Post-IPO Growth: Monetisation will follow the typical lock-in, but the rerate sets the stage. A Nasdaq-listed asset is a liquid asset, fundamentally shifting TEK’s risk profile.

The Evolution: We’re not just waiting for a listing; we’re waiting for the market to realise the value of years of IP development.

Some investors are zooming in on just one piece of the puzzle here. That’s where confusion creeps in. Tekcapital isn’t a single-story play - it’s a multi-engine model, and you only really “get it” when you step back and see how all parts connect.

Here’s the framework in a nutshell:

1) The Engine Room (IP Creation & Acquisition)Tek finds, develops, or acquires intellectual property with commercial potential. This is the raw fuel - early-stage, often overlooked innovations.

2) The Value Builder (Spin-outs / Subsidiaries)Instead of sitting on IP, they package it into focused companies (Guident, MicroSalt, etc.). Each one becomes its own growth story with clearer valuation potential.

3) The Catalyst Events (IPOs / Listings / Deals)This is where value starts to crystallise. IPOs, strategic deals, or partnerships unlock pricing the market can actually see - often far above “hidden” book value.

4) The Flywheel Effect (Reinvestment & Repeat)Proceeds and uplift feed back into the system. New IP ➡️ new spin-outs ➡️ new catalysts. It’s not a one-off - it’s a cycle.

5) The Gap (Where Opportunity Lives)The market often values Tekcapital on current visibility, not forward pipeline. That gap between what’s visible today and what’s quietly developing is where the upside sits.

The Key Point:If you only focus on one piece (e.g. just an IPO, or just one subsidiary), you miss the compounding effect of the whole machine.

Tekcapital isn’t just a stock - it’s a process.And the process is where the real value builds over time.

Those who see one tree might trade it.

Those who see the forest tend to hold it.

The Calm Before the Storm. 🌪️

The Guident IPO is the first domino. But when it falls, the ripple effects will lead to a few surprises. Not everything has been revealed yet, and what’s in the works is bigger than most people realize.

We’re in the window now - just waiting on the next step (IPO)

Fair point - and that’s where it all ties together.

GDNT getting a live market valuation is the key piece here.

Once that’s established, TEK’s discount stops being a talking point and starts being something the market has to reconcile.

We’re past the childness opinions now - the next step is IPO pricing.

Effectiveness ➡️ pricing ➡️ price discovery. That’s the only sequence that matters.

And here’s where it gets interesting…

As GDNT establishes a market value, TEK’s discount is starting to get challenged.

This is the transition from “potential” to “repricing”.

Effectiveness is the unlock.

Then it’s about IPO pricing and where the market chooses to value GDNT on day one.

That number feeds directly into TEK’s SOTP - and that’s where the rerate becomes real.

There’s a persistent claim that every placing is just insiders lining their pockets

I don’t buy that - and more importantly, the history doesn’t support it.

If you actually step back and look at how these placings have been used, a different picture emerges:

They’ve consistently been timed around portfolio progression points and delays, not randomly. When timelines slip (as they often do with listings, regulatory processes, or macro disruptions), cash burn doesn’t magically pause. Costs still exist - staffing, development, legal, listing prep.

So management has two choices:

Sit tight and risk starving assets at critical stages

Raise capital, protect momentum, and keep each company moving towards monetisation

They’ve clearly chosen the second.

And that’s the key point most are missing:

These aren’t placings to create value out of thin airThey’re placings to protect and unlock value that already exists

If anything, it shows a preference for:

keeping portfolio companies funded through delays

avoiding distressed outcomes

maintaining optionality ahead of key events (like IPOs)

Could they be better timed from a shareholder perspective? Sure - that’s always debatable.

But to suggest they’re done purely for personal gain ignores the bigger picture:Without those raises, several assets likely don’t reach the stage where they can even be monetised.

In venture-style investing, timing is rarely perfect - but survival and progression matter more than optics.

So the real question isn’t:“Why did they raise?”

It’s:“Did those raises increase the probability of successful exits?”

From where I’m sitting - the answer to that is yes.

From a pure technical chart point of view, the first big test for me is the multi‑layered resistance zone around 12p. If TEK can break and hold above that post‑Guident, it would confirm a more meaningful reversal in my eyes. Beyond that, there’s a longer‑term possibility of a full “circle” back towards the mid‑30s over time, but that would depend on how Guident trades and how quickly the market is prepared to close the discount.

How I’m thinking about trimming (not advice):

If Guident’s IPO leads to a genuine re‑rate in TEK and the discount to my own SOTP view narrows to something more “normal”, I’ll look at trimming into strength during the post‑IPO/180 day - lock‑up window. If the discount stays extreme, I’m more likely to keep holding and let the re‑pricing story play out.

🚀 What comes next (the part some people underestimate)

5️⃣ Price Discovery ➡️ Re-rate Phase

This is where things get interesting:

A live NASDAQ price replaces estimates

TEK’s stake becomes visible and trackable in real time

The market can no longer say “we don’t know what it’s worth”

So the conversation shifts from:

“Is it worth X?”

to:

“Why is TEK trading at Y when its stake implies Z?”

1️⃣ Identify & Acquire

University IP ➡️ secured early at low cost

2️⃣ Build & Validate

Develop tech ➡️ prove commercial viability ➡️ reduce risk

3️⃣ Private Funding Rounds

External capital sets benchmark valuations

4️⃣ IPO Event (Key Catalyst)

Subsidiary lists (e.g. Guident) ➡️

➡️ moves from internal/book value ➡️ live market price

5️⃣ Price Discovery

NASDAQ trading establishes real-time valuation

➡️ uncertainty removed

➡️ value becomes measurable

6️⃣ Look-Through Revaluation

TEK’s stake now tied to a visible market cap

➡️ SOTP becomes harder to ignore

➡️ discount to NAV becomes contestable

7️⃣ Monetisation Pathways

Partial stake sales

Dividends upstream

Strategic deals / exits

8️⃣ Capital Recycling

Proceeds reinvested into new IP

➡️ cycle repeats

In short:

IP ➡️ Build ➡️ IPO ➡️ Price Discovery ➡️ Re-rate ➡️ Monetise ➡️ Repeat

They wake at six to check the feed,

With desperate, daily, bearish greed.

"Tuffax" and "Aspers" – the tragic pair,

Trading insults for lack of a prayer.

They’ve archived every old RNS,

To build a shrine of past distress.

But while they lived in 2022,

The Nasdaq S‑1 slipped right through.

A 70% stake, a "free" IPO,

While they’re still shouting at ghosts below.

The logic is simple, the math is quite clear:

The biggest "discount" is between their ears.

🎤✨

Some are still anchored to past patterns:

“IPO happens ➡️ TEK barely moves.”

Others are focused on what’s actually changing now:

uncertainty removed ➡️ valuation becomes measurable ➡️ discount becomes contestable.

With Guident listed, the final major unknown becomes a live market input – and the case for a wide discount becomes much harder to justify.

Time will show who was on the right side of this.

Focus remains on the same point:

effectiveness → IPO → live valuation.

That’s where the market gets clarity.

Bears are stuck in their self-imposed echo chamber, endlessly repeating the same failed narratives. Meanwhile, Tekcapital’s ecosystem is growing, evolving, and positioning itself for success. The bears may think they’re loud, but they’re irrelevant in the face of real growth.

For me the story is simple: Guident moving from Tek’s internal/book value to a live NASDAQ price is the key catalyst. Once the market can see a screen price for GDNT, the discount to TEK’s SOTP has to be re‑examined.

This isn’t a bull case or a hope case.

It’s simply mapping how a listed valuation for Guident feeds through into TEK’s look-through value.

A live NASDAQ valuation replaces estimation with price discovery.

The market will decide how much of that gets priced in.

Interesting how the naysayers narrative evolves…

First it was “no IPO”, now it’s “what price IPO”.

That shift alone tells you where we are in the process.

All eyes 👀 on the next SEC/EDGAR filing.

If Guident trades well and MicroSalt/GenIP execute, TEK’s SOTP itself rises, so there’s scope for both:

NAV/SOTP going up, and

The discount to that NAV narrowing.

I’m not putting specific share price targets on TEK. My view is simply that effectiveness + a successful Guident IPO should, over time, shift the market from valuing TEK on MicroSalt alone to recognising the combined value of SALT, GDNT and GNIP, with any narrowing of the holding‑company discount as upside on top.